Substance use disorder

New report highlights mental health challenges facing women veterans

Retrieved on: 
Tuesday, February 27, 2024

DAV’s report, Women Veterans: The Journey to Mental Wellness , is the most comprehensive assessment of the unique factors contributing to the staggering rates of suicide among women veterans and how the system charged with their mental health care—the Department of Veterans Affairs (VA)—can and must do better.

Key Points: 
  • DAV’s report, Women Veterans: The Journey to Mental Wellness , is the most comprehensive assessment of the unique factors contributing to the staggering rates of suicide among women veterans and how the system charged with their mental health care—the Department of Veterans Affairs (VA)—can and must do better.
  • Gaps in mental health care: DAV’s report reveals the need to improve access to mental health care that accounts for the unique risk factors women veterans face, improve suicide prevention efforts among women veterans, and invest in further research and data collection that proportionally represents women veterans.
  • Understanding: The impact of reproductive health life stages on mental health and suicide risk among women veterans is woefully understudied and not well defined.
  • Women Veterans: The Journey to Mental Wellness is DAV’s third report focused on the unique experiences and needs of women veterans.

Netsmart Supports Whole-Person Care Provisions in 42 CFR Part 2 Final Rule

Retrieved on: 
Tuesday, February 20, 2024

Strengthens penalties by applying the same requirements of the HIPAA Breach Notification Rule to breaches of records under Part 2.

Key Points: 
  • Strengthens penalties by applying the same requirements of the HIPAA Breach Notification Rule to breaches of records under Part 2.
  • As a founding member of The Partnership to Amend 42 CFR Part 2 , Scalia stated the long-awaited Final Rule is another step forward for coordinated, whole-person care for individuals nationwide.
  • These major changes to 42 CFR Part 2 will take effect on February 16, 2026.
  • To learn more about these regulation changes, read the 42 CFR Part 2 Final Rule Fact Sheet and register for the upcoming Netsmart webinar on Thursday, March 28 at 1 p.m.

Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements

Retrieved on: 
Tuesday, January 16, 2024

Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.

Key Points: 
  • Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.
  • Led by SPRIM Global Investments Pte, Ltd, with key participation from core investors, this funding includes a $3.8 million credit facility.
  • Alongside these key developments, Stalicla will further strengthen the package supporting its second precision ASD asset, STP2.
  • Lynn Durham, CEO of Stalicla commented: “This financial backing underscores Stalicla's role as a trailblazer in the neuro precision space with first applications in precision psychiatry.

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

Retrieved on: 
Thursday, November 30, 2023

NEW HAVEN, Conn., Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a virtual Neuroscience R&D Day from 1:00 to 2:30 p.m. ET on Tuesday, Dec. 12, 2023.

Key Points: 
  • NEW HAVEN, Conn., Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a virtual Neuroscience R&D Day from 1:00 to 2:30 p.m.
  • He has published nearly 900 articles and 44 books devoted to neuroscience, Alzheimer’s disease, and clinical trials.
  • To access the virtual R&D Day presentation, please dial 877-407-5795 (domestic) or 201-689-8722 (international).
  • BioXcel Therapeutics may use its website as a distribution channel of material information about the Company.

The Haven Detox Expands with New Location in West Memphis, Arkansas

Retrieved on: 
Friday, December 8, 2023

WEST MEMPHIS, Ark., Dec. 8, 2023 /PRNewswire/ -- The Haven Detox , a leading provider of comprehensive detoxification and addiction treatment services, announced the opening of its newest detox facility in West Memphis , Arkansas, today.

Key Points: 
  • WEST MEMPHIS, Ark., Dec. 8, 2023 /PRNewswire/ -- The Haven Detox , a leading provider of comprehensive detoxification and addiction treatment services, announced the opening of its newest detox facility in West Memphis , Arkansas, today.
  • This strategic expansion highlights The Haven's commitment to providing accessible and high-quality care to communities grappling with substance use disorder.
  • Since its founding, The Haven Detox has become renowned for its progressive approach to addiction treatment, seamlessly integrating evidence-based therapies with holistic wellness practices.
  • To learn more about The Haven Detox West Memphis, visit https://arkansasrecovery.com/

Rigby named Chief Development Officer for Capstone Wellness

Retrieved on: 
Monday, November 20, 2023

SEARCY, Ark., Nov. 20, 2023 /PRNewswire-PRWeb/ -- Capstone Wellness has been dedicated to assisting individuals and families in overcoming challenges related to trauma, substance abuse, mental health struggles, attachment issues, sexual compulsions, addictive behaviors, and more for over two decades.

Key Points: 
  • Capstone Wellness announced today that Ruth Ann Rigby, CRS, is returning home to Capstone as a member of their leadership team in the role of Chief Development Officer.
  • Dr. Adrian Hickmon, Founder of Capstone, expresses, "We are thrilled to welcome Ruth Ann Rigby back to our Capstone family.
  • Slade Hickmon, chief executive officer at Capstone, adds, "Ruth Ann Rigby's dedication to helping those struggling with addiction is truly remarkable.
  • In Ruth Ann's own words, "I am humbled and honored to return home to continue to grow our company with Capstone Wellness.

AltaPointe Health's Supported Employment Program Empowers Individuals with Serious Mental Illness to Find Meaningful Work and Independence

Retrieved on: 
Sunday, November 12, 2023

MOBILE, Ala., Nov. 12, 2023 /PRNewswire-PRWeb/ -- Supported employment for people living with a serious mental illness or co-occurring substance use disorder is a specialized approach to help individuals find and maintain meaningful employment. Supported Employment emphasizes that work is not the result of treatment and recovery but integral to both.

Key Points: 
  • Since 1987, the AltaPointe Supported Employment program has been helping individuals enter or re-engage with the workforce through competitive employment.
  • MOBILE, Ala., Nov. 12, 2023 /PRNewswire-PRWeb/ -- Supported employment for people living with a serious mental illness or co-occurring substance use disorder is a specialized approach to help individuals find and maintain meaningful employment.
  • "AltaPointe's Supported Employment program is a valuable service that recognizes the unique challenges individuals diagnosed with a serious mental illness face and strives to create inclusive and supportive work environments where they can thrive.
  • The argument that individuals with a serious mental illness should not or cannot work is empty, as many can and do work effectively.

AANA Updates, Publishes Analgesia and Anesthesia Practice Considerations for The Substance Use Disorder Patient

Retrieved on: 
Wednesday, October 25, 2023

"Effective analgesia and anesthesia care for the substance use disorder patient involves managing the physiological and psychological implications of substance use, mitigating withdrawal, and preventing relapse," said Daniel King, DNP, CRNA, CPPS, AANA Practice Committee chair.

Key Points: 
  • "Effective analgesia and anesthesia care for the substance use disorder patient involves managing the physiological and psychological implications of substance use, mitigating withdrawal, and preventing relapse," said Daniel King, DNP, CRNA, CPPS, AANA Practice Committee chair.
  • "The purpose of these practice considerations is to offer evidence-based guidance for the anesthesia professional in the provision of optimally safe care for the SUD patient.
  • AANA's updated practice considerations offer insight on providing optimal care for all patients with substance abuse disorder, with special emphasis for patients using cannabis.
  • Other benefits of multimodal analgesia include early mobilization, decreased length of stay, faster functional recovery, decreased pain scores, and increased patient satisfaction.

Lifesaving Platform, Shatterproof Treatment Atlas, Coming to Connecticut to Address the Addiction Crisis

Retrieved on: 
Monday, October 23, 2023

Together, they will announce a new Shatterproof resource that is being offered throughout Connecticut to assist residents with substance use disorders, support those impacted by substance use disorders, and mobilize those in recovery.

Key Points: 
  • Together, they will announce a new Shatterproof resource that is being offered throughout Connecticut to assist residents with substance use disorders, support those impacted by substance use disorders, and mobilize those in recovery.
  • Shatterproof is the leading grassroots organization committed to removing systemic barriers to recovery, mobilizing the country to advocate for change, and ending addiction stigma, and Shatterproof Treatment Atlas is a state-funded project.
  • Treatment Atlas, a lifesaving solution that highlights high-quality addiction treatment options, will become available to help thousands of residents find addiction treatment that will meet their unique needs.
  • The development of the Connecticut section of Treatment Atlas is funded by a grant from DMHAS.

Lifesaving Platform, Shatterproof Treatment Atlas, Coming to Connecticut to Address the Addiction Crisis

Retrieved on: 
Tuesday, October 17, 2023

This National Addiction Treatment Week (October 19-25), the State of Connecticut Department of Mental Health and Addiction Services (DMHAS) Deputy Commissioner Colleen Harrington, LCSW, MBA; Shatterproof Founder and CEO Gary Mendell; and Shatterproof Ambassador Dita Bhargava will unveil a historic lifesaving tool on Tuesday, October 24 at 9 a.m. Eastern.

Key Points: 
  • This National Addiction Treatment Week (October 19-25), the State of Connecticut Department of Mental Health and Addiction Services (DMHAS) Deputy Commissioner Colleen Harrington, LCSW, MBA; Shatterproof Founder and CEO Gary Mendell; and Shatterproof Ambassador Dita Bhargava will unveil a historic lifesaving tool on Tuesday, October 24 at 9 a.m. Eastern.
  • Shatterproof is the leading grassroots organization committed to removing systemic barriers to recovery, mobilizing the country to advocate for change, and ending addiction stigma, and Shatterproof Treatment Atlas is a state-funded project.
  • Treatment Atlas, a lifesaving solution that highlights high-quality addiction treatment options, will become available to help thousands of residents find addiction treatment that will meet their unique needs.
  • The development of the Connecticut section of Treatment Atlas is funded by a grant from DMHAS.